SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. We are looking for talented, motivated, dynamic employees to join our international ...
SOTIO aims to become a diverse oncology company that develops early stage candidates into marketed immunotherapy products. We seek to add to our portfolio projects that are at advanced preclinical or clinical stages.
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that the first patient was dosed in its Phase 2 AURELIO-05 combination trial of nanrilkefusp alfa ...
Nanrilkefusp alfa (formerly SOT101) is an IL-15 superagonist that has been precisely designed and optimized for its use as a potent immunotherapy. It is currently being studied in an ongoing Phase 1/1b study …
SOTIO’s BOXR cell therapy platform is designed to improve the functionality of engineered T cells by identifying novel “bolt-on” transgenes that can be co-expressed with tumor-targeting receptors to overcome resistance and improve the function of T cells in the solid tumor microenvironment.
SOTIO’s proprietary antibody-drug conjugate (ADC) platform yields potent and highly stable ADCs with a wide therapeutic window for the treatment of cancer …